ZEISS Ventures

Mirae Asset Capital Life Science was formed in 2023 as a joint venture between Mirae Asset Capital and Mirae Asset Global Investments. It is the first and only U.S. affiliate for Mirae Asset dedicated to investment in Life Science. Near-Term ValueThe majority of our investments will be Series A/B and entering the clinic within a few years to generate real value with clinical proof of concept We believe companies at this stage maximize returns given the risk; we remain open to seed opportunities where there is a clear path to value and Series C opportunities if the valuation and resulting equity ownership support meaningful returns to our investors We aim to find the right mix between first-in-class and best-in-class assets with meaningful market share and evaluate both platform and single asset approaches Calculated RiskWe are modality agnostic when it comes to therapeutics and incredibly opportunistic with diagnostics Our interest in digital health involves using AI/ML tools (e.g. quantum computing, generative biology/chemistry) for drug discovery or protein engineering We co-invest with top-tier life science investors who we know and have worked with before and leverage our operational experience to find strong management teams with excellent track records relevant to the company they are building We aim to be active investors by securing board roles whenever possible; this is a role that is familiar to us and helps mitigate risk to our investors by helping to shape the course of our investments Innovative yet Validated ModalitiesWe have selected five core therapeutic sectors to focus our investments: Oncology, Immunology, CV/Metabolic, CNS/Ophthalmology, and Rare/Genetic Disease For each of the above sectors we have defined various focus areas defined by a unique combination of validation, unmet need, market potential, and acquisition/public market interest We seek to limit biological and technical risk and prioritize small molecule, antibody approaches (includes mAbs, bsAbs/TCEs, ADCs, radiotherapeutics), and nucleic acid therapeutics (siRNA, ASOs) across these sectors Rigorous EvaluationWe leverage the combined scientific background of our team and our affiliates in Asia (medicinal chemistry, pharmacology, structural biology) to perform rigorous evaluation of each investment We prepare a comprehensive diligence memo for each investment that includes a thorough evaluation of the science, pipeline, finance, management, board, investors, operations, regulatory, IP, clinical development, and potential return to our investors We conduct calls with relevant Key Opinion Leaders for every opportunity to ensure we have the most informed and updated views from the leading voices in the field

Our unique model combines first access and proprietary rights to disruptive deal flow with an established track record of new venture formation, company building, and value creation. We invest in bold, transformative innovations to develop new drugs and technologies to improve outcomes for the market benefit of patients worldwide. Investing in early-stage venture capital We invest in seed and early-stage life science ventures, bringing Mass General Brigham’s expertise and extensive network to bear to create transformative solutions to solve unmet medical needs. Leveraging a competitive advantage Research is the driving force that advances medicine and Mass General Brigham Ventures sits at the center of the largest medical research engine in the United States. #1 in hospital medical research​ Mass General Brigham Ventures is a member of the largest hospital system-based research enterprise in the U.S., which includes Massachusetts General Hospital and Brigham and Women’s Hospital, two of the nation’s premier academic medical centers whose origins date back to the early 1800’s.​ Mass General Brigham Ventures' unique model leverages a preferred position to source technology including first access and rights to disruptive deal flow. This is an exceptional advantage that conventional venture capital funds cannot reproduce. Legacy of investing in medical innovation Mass General Brigham Ventures plays a key role in founding and funding next-generation technologies. These three transformational companies are examples of start-ups that are poised to address significant unmet medical needs. All were seeded by Mass General Brigham Ventures with founding intellectual property from Mass General Brigham. Editas Medicine: IPO Feb. 2016 (NASDAQ: EDIT) Unlocking the power and potential of CRISPR genome editing technology. CoStim Pharmaceuticals: Acquired by Novartis, Feb. 2014 Next-generation immuno-oncology drugs based on T-cell costimulatory targets. Keros Therapeutics: IPO April 2020 (NASDAQ: KROS) Novel treatments for patients suffering from hematologic and musculoskeletal disorders. Our investment strategy We invest in next-generation life science companies based on intellectual property created within our own research community. We seek strong co-investor syndicates to develop products across a range of categories including drugs, devices, diagnostics, and digital health.​ Initial investments are directed at the seed and Series A stages, where our participation attracts capital and talent into the most difficult-to-fund phase of company development. When we invest, we expect to support each portfolio company through its entire financing lifecycle. In addition to providing the necessary venture capital, we leverage our experience in starting and growing companies, our expertise in the medical industry, and our network of scientific and business talent to build great companies. Leveraging a proven approach:The annual output of high-impact invention and discovery represents a unique opportunity to create, finance, and monetize new life science-based companies. We deploy start-up capital to capture the collective expertise of our unrivaled base of scientific talent and clinical resources to bring cutting-edge science to patients Competitive advantage of Mass General Brigham: The power of collective impact from our vast research enterprise provides an unrivaled competitive advantage to build next generation life science companies capable of bringing innovative therapeutics to patients in need and delivering outstanding returns to our investors. Academic medical centers: We source deals from our five research and teaching hospitals, which collectively represent the largest teaching affiliate of Harvard Medical School.

82VS is our affiliated venture studio that pairs Alloy’s platforms and services with a team of company creation experts to efficiently launch new asset-centric companies. Alloy works with exceptional founders, entrepreneurs- and executives-in-residence, and biotech and pharma partners to develop new medicines by efficiently leveraging the capabilities of the Alloy ecosystem at large. The 82VS name comes from the atomic number for lead, 82. To us, lead represents the most boring of metals that can form alloys, frequently used in low-cost solder to bring other metals together. This is because we seek to be behind the scenes and to fade into the background as we let our entrepreneurs and their companies take the credit for their great work. We Partner We partner with academics, entrepreneurs, target-rich companies, pharma, and VC. We lead with our drug discovery work, helping others advance targets of interest. We Build We build asset-focused companies while continuing to incorporate new modalities and drug discovery platforms accessible throughout the Alloy ecosystem. Alloy creates new platforms and services on demand to support individual new companies if needed. We Industrialize We industrialize repeatable company launch processes across legal, HR, finance, operations, and marketing to minimize startup time and allow scientists to focus on the science. Our People We come from pharma, biotech, academia, and venture capital backgrounds. Our EIRs can pursue their scientific ideas with full operational support and can repeatedly harness the 82VS infrastructure to create more value. We launch new companies and support strategic investments Collectively the companies supported out of 82VS are pursuing next generation innovative treatments for cancer, neurodegeneration, autoimmune disease, hereditary blindness, and more. Our investments in next-generation manufacturing companies help our ecosystem of partners advance more quickly to the clinic. We create, in-license, and co-develop pre-competitive enabling technology platforms that help the entire drug discovery community move faster. We value the work of inventors, ensuring your work lands with maximum impact. There is nothing more frustrating to a scientist or engineer than to see their life’s work trapped inside one company and only able to be accessed and improved by a single team. Alloy’s mission is to unlock the potential of pre-competitive technologies by taking a very long view of investing in platform development and helping our partners and venture studios utilize these technologies as aggressively as possible. Generally, platform technology continues to be improved over time and with greater use and engagement from the ecosystem. It’s exciting to think that the technologies we invent today will be supported, improved and available to our ecosystem today and long into the future. Alloy reinvests 100% of our revenue back into innovation and access to innovation while sharing the value with the innovators themselves.

We invest in the innovators behind the miracles of science who are passionate about improving human health. Sanofi Ventures serves as an entry point to the innovation ecosystem for Sanofi, strategically investing in early-stage transformational science and technology, when companies are too early to partner with or acquire. Our Approach As the corporate venture capital arm of Sanofi, we invest in top-tier biotech and digital health companies that focus on helping patients and transforming the practice of medicine. We invest across all stages of the private company lifecycle, from Seed to Series B and beyond, while leading financings, serving on boards, and taking pride in working alongside portfolio companies to drive long-term value through future financings and IPO. How We Work Think of us like institutional venture capitalists with an added bonus: in addition to our investment, we aim to offer our portfolio companies select access to Sanofi’s expertise and capabilities in science, preclinical and clinical development, regulatory, data analytics, manufacturing, market access, and commercialization. Our goal is to foster strong relationships over time so when our portfolio company is ready to consider a partnership or acquisition, our colleagues on the BD and M&A teams can be a first and last call. We move quickly, we don’t believe in drawn-out processes, and we always aim to provide thoughtful feedback. Our Investment Focus We invest in early-stage biotech and digital health companies of strategic interest to Sanofi. We seek to accelerate all strategic focus while reaching into novel and emerging areas of science and technology. Here are some of the areas that we currently are thinking about: Rare diseases Immunology and inflammation Oncology Cell and gene therapy Vaccines Digital health and data science We can't do it alone - we would love to hear how we can team up to improve human health for people everywhere!

We are in the midst of technological shifts at a pace faster than ever before. Calculus VC capitalizes on these shifts to deliver returns and impact. We invest in the Series A and Series B stages of startups in the below sectors: FUTURE OF COMPUTING AND AI Continued advancements in AI will demand new developments in hardware and software. New computing materials and interfaces may emerge. Computing power may be more distributed, and the world will be infinitely more connected. These and more, are our areas of interest: Intelligence beyond language: We expect AI to understand quantitative models and physical phenomenon just as well as it understands language. Large Quantitiative Models are a focus for us. New hardware, materials, and architectures: We expect that demand for computing power will grow exponentially. Quantum computing, as well as distributed computing are expected to grow. We expect advancements in computing materials beyond silicon. Immersive and neural interfaces: These interfaces already exist, we expect they will become more mainstream. Spatial computing, integrating the physical world with digital environments may be our future. COMPUTATIONAL LIFE SCIENCES AND HEALTHTECH Breakthroughs in biology, materials, sensors, and data science are converging to redefine healthcare. Precision and personalization will take center stage as AI enhances how we detect, monitor, and treat disease. Areas of interest include: AI-First Therapeutics and Discovery Platforms: ML-powered platforms designing drugs and biologics via simulation, predictive modeling, and data-rich experimentation. Infrastructure for Programmable Biology: Tools that make biology engineerable – lab automation, bioinformatics, 3D bioprinting, next-gen diagnostics and R&D devices. Continuous, Data-Driven and Personalized Care: Wearables, medical devices, and diagnostics to deliver patient-centric care. These models turn users into real-time data streams, enabling adaptive treatment and personalized interventions. ADVANCED INDUSTRIAL TECHNOLOGIES As we expand the frontiers of possibility, we expect industry to evolve with intelligence, autonomy and environmental sustainability at its core. Areas of focus include: AI and automation in industry: Intelligent machines will optimize production, reduce waste, and enable new workflows. From predictive maintenance to robotic manufacturing, automation will power the next industrial revolution. We support startups enabling this vision. Land, ocean, and space transport and communications: We are interested in advanced materials, robotics, sensors, systems and software that will unlock new frontiers from deep-sea mapping to planetary missions. Resource efficiency: Building the future will demand large reserves of energy and natural resources. Technologies that can serve our energy, food, water, and agricultural needs while supporting a better planet are of interest to us.

Cybernetix Ventures is a venture capital firm leading the way for investment into early-stage robotics, automation, and AI startups. Headquartered in Boston, the world’s epicenter for robotics innovation, Cybernetix connects its portfolio to the national and global robotics ecosystems, bringing unparalleled expertise to companies poised to make major impacts in sectors including advanced manufacturing, logistics/warehousing, architecture, engineering and construction and healthcare/medical devices. The fund will also invest in key robotics-enabling software companies in AI/machine learning, cloud robotics, cybersecurity, autonomy, and sensors/edge computing.